📊 BTAI Key Takeaways
Is BioXcel Therapeutics, Inc. (BTAI) a Good Investment?
BioXcel is in severe financial distress with negative stockholders' equity of -$88.9M, massive operating losses (-$40.2M), and severe cash burn (-$43.4M operating cash flow). The company is generating minimal revenue ($386K) while burning substantial cash, making near-term survival questionable without significant capital infusion.
BioXcel Therapeutics shows extremely weak fundamentals: revenue remains negligible relative to its cost base, operating losses are massive, and free cash flow is deeply negative. The balance sheet is highly stressed with negative equity and substantial long-term debt, leaving the company dependent on external financing unless commercialization or expense structure improves materially.
Why Buy BioXcel Therapeutics, Inc. Stock? BTAI Key Strengths
- Positive revenue growth of 64.2% YoY shows emerging product traction
- Cash position of $36.2M provides short-term runway for operations
- Current ratio of 1.17x indicates near-term liquidity is not immediately critical
- Revenue grew 64.2% year over year, indicating some commercial or collaboration traction from a very small base
- Cash and equivalents of $36.18M provide limited near-term operating flexibility
- Current and quick ratios slightly above 1.0 suggest short-term liquidity is not yet fully impaired
BTAI Stock Risks: BioXcel Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$88.9M indicates the company is technically insolvent on a balance sheet basis
- Operating cash burn of -$43.4M annually with only $36.2M cash suggests runway of less than one year without additional funding
- Extreme operating losses and net losses despite growth suggest business model is fundamentally unprofitable and may not achieve viability
- Long-term debt of $109.1M far exceeds total assets of $44.8M, creating unsustainable capital structure
- Minimal revenue base of $386K insufficient to service debt or fund operations at current burn rate
- Profitability is severely negative, with operating margin of -10409.1% and net margin of -14858.0%, showing an unsustainable cost structure
- Negative stockholders equity of -$88.92M and $109.12M of long-term debt indicate a highly impaired capital structure
- Operating cash flow and free cash flow of -$43.41M imply ongoing cash burn and likely future financing pressure
Key Metrics to Watch
- Quarterly revenue growth trajectory and path to profitability
- Cash runway and timing of next capital raise requirement
- Operating cash flow burn rate and working capital efficiency
- Quarterly operating cash burn relative to cash balance
- Revenue scale-up versus operating expense reduction
BioXcel Therapeutics, Inc. (BTAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
BioXcel Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BTAI Profit Margin, ROE & Profitability Analysis
BTAI vs Healthcare Sector: How BioXcel Therapeutics, Inc. Compares
How BioXcel Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioXcel Therapeutics, Inc. Stock Overvalued? BTAI Valuation Analysis 2026
Based on fundamental analysis, BioXcel Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioXcel Therapeutics, Inc. Balance Sheet: BTAI Debt, Cash & Liquidity
BTAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioXcel Therapeutics, Inc.'s revenue has grown significantly by 504% over the 5-year period, indicating strong business expansion. The most recent EPS of $-23.51 indicates the company is currently unprofitable.
BTAI Revenue Growth, EPS Growth & YoY Performance
BTAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $98.0K | -$7.3M | $-2.18 |
| Q2 2025 | $120.0K | -$7.3M | $-2.45 |
| Q1 2025 | $168.0K | -$7.3M | $-1.50 |
| Q3 2024 | $214.0K | -$8.3M | $-0.32 |
| Q2 2024 | $457.0K | -$8.3M | $-0.21 |
| Q1 2024 | $206.0K | -$26.8M | $-0.87 |
| Q3 2023 | $137.0K | -$31.5M | $-1.49 |
| Q2 2023 | $457.0K | -$31.5M | $-1.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioXcel Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
BTAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioXcel Therapeutics, Inc. (CIK: 0001720893)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BTAI
What is the AI rating for BTAI?
BioXcel Therapeutics, Inc. (BTAI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BTAI's key strengths?
Claude: Positive revenue growth of 64.2% YoY shows emerging product traction. Cash position of $36.2M provides short-term runway for operations. ChatGPT: Revenue grew 64.2% year over year, indicating some commercial or collaboration traction from a very small base. Cash and equivalents of $36.18M provide limited near-term operating flexibility.
What are the risks of investing in BTAI?
Claude: Negative stockholders' equity of -$88.9M indicates the company is technically insolvent on a balance sheet basis. Operating cash burn of -$43.4M annually with only $36.2M cash suggests runway of less than one year without additional funding. ChatGPT: Profitability is severely negative, with operating margin of -10409.1% and net margin of -14858.0%, showing an unsustainable cost structure. Negative stockholders equity of -$88.92M and $109.12M of long-term debt indicate a highly impaired capital structure.
What is BTAI's revenue and growth?
BioXcel Therapeutics, Inc. reported revenue of $386.0K.
Does BTAI pay dividends?
BioXcel Therapeutics, Inc. does not currently pay dividends.
Where can I find BTAI SEC filings?
Official SEC filings for BioXcel Therapeutics, Inc. (CIK: 0001720893) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BTAI's EPS?
BioXcel Therapeutics, Inc. has a diluted EPS of $-6.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BTAI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioXcel Therapeutics, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BTAI stock overvalued or undervalued?
Valuation metrics for BTAI: ROE of N/A (sector avg: 15%), net margin of -14,858.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BTAI stock in 2026?
Our dual AI analysis gives BioXcel Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BTAI's free cash flow?
BioXcel Therapeutics, Inc.'s operating cash flow is $-43.4M, with capital expenditures of $0.0. FCF margin is -11,244.8%.
How does BTAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,858.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.17 (avg: 2).